7 Grants
2008
Rituximab Treatment of Focal Segmental Glomerulosclerosis
Pescovitz, Mark D
National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (ID: 3R21DK077329-01A1S1), $33,783USD, 09/30/2007 -- 08/31/2009
 
Rituximab Treatment of Focal Segmental Glomerulosclerosis
Pescovitz, Mark D
National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (ID: 5R21DK077329-02), $184,043USD, 09/30/2007 -- 08/31/2010
2007
Rituximab Treatment of Focal Segmental Glomerulosclerosis
Pescovitz, Mark D
National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (ID: 1R21DK077329-01A1), $189,580USD, 09/30/2007 -- 08/31/2009
2004
Assessment of the ANTI-phiX174 Antibody Response in Dialysis Patients
Pescovitz, Mark D
National Institutes of Health (NIH), National Center for Research Resources (NCRR) (ID: 5M01RR000750-32), $6,977USD, 12/01/2003 -- 11/30/2004
1999
GANCICLOVIR AFTER VALGANCICLOVIR, GANCICLOVIR IN LIVER TRANSPLANT
Pescovitz, Mark D
National Institutes of Health (NIH), National Center for Research Resources (NCRR) (ID: 3M01RR000750-27S3), 12/01/1998 -- 11/30/1999
1997
SAFETY AND TOLERABILITY OF NEORAL IN STABLE RENAL TRANSPLANT PATIENTS
Pescovitz, Mark D
National Institutes of Health (NIH), National Center for Research Resources (NCRR) (ID: 5M01RR000750-25), 03/13/1997 -- 11/30/1997
1996
SAFETY AND TOLERABILITY OF NEORAL IN STABLE RENAL TRANSPLANT PATIENTS
Pescovitz, Mark D
National Institutes of Health (NIH), National Center for Research Resources (NCRR) (ID: 5M01RR000750-24), 1996